Takeda Pharmaceutica

4502
End-of-day quote Tokyo - 02/19
4500JPY
-0.18%
Prev.4508.0000
Open4508.0000
High4533.0000
Low4481.0000
Volume4 781 100
Financials
Sales 2019 2 463 B
EBIT 2019 -
R. net 2019 180 B
Debt 2019 5 789 B
Rend. 2019 3,99%
P/E ratio 2019 33,60
P/E ratio 2020
EV / Sales 2019 5,21x
EV / Sales 2020 3,53x
Capitalization 7 055 B
Company
Takeda Pharmaceutical Company specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. Net sales break down by activity as follows:
- sale of drugs (95.5%);
- sale of...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-03-25 Presentation
Trading Rating :
Investor Rating :
Latest news
02/18TAKEDA PHARMACEUTICAL : Notice Regarding Issue of Hybrid Bonds to replace Senior Short Term Loan
AQ
02/15TAKEDA PHARMACEUTICAL : Urgent Headline News
AQ
02/15TAKEDA PHARMACEUTICAL : Shire's Full Year 2018 Results
PU
02/15TAKEDA PHARMACEUTICAL : Notice Regarding Issue of Hybrid Bonds to replace Senior Short Term Loan (Offering of Subordinated Bonds)
PU
02/11TAKEDA PHARMACEUTICAL : European Commission Approves ADCETRIS with AVD for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
PU
02/11TAKEDA PHARMACEUTICAL : European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma
BU
02/09TAKEDA PHARMACEUTICAL : Announces Results from First Trial
AQ
02/08Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralNeutralBearish
Resistance4 5094 8994 627
Spread/Res.-0,20%-8,1%-2,7%
Spread/Supp.7,1%25%21%
Support4 2003 5883 705